TOP HEADLINES

Featured Story

Neuwave Medical reels in $25M for minimally invasive ablation device

Neuwave Medical roped in $25 million in equity funding to support development of its soft tissue ablation system, ramping up operations as it expands the reach for its innovative surgical system.

Boston Scientific VP explains its plans to enter the leadless pacing market

Boston Scientific revealed more details about its leadless pacemaker program, as it seeks to join Medtronic and St. Jude Medical in that market (which does not yet exist in the U.S., where the devices are still being investigated).

FDA to allow midstream changes to device trials as part of effort to speed up approvals

The FDA issued draft guidance this week on adaptive designs for medical device clinical studies. Similar to a prior guidance on the incorporation of patient preference data in clinical trials, the latest guidance should help companies perform trials faster, and signals greater flexibility on the behalf of the FDA.

Medtronic's Ishrak setting his sights on India for future growth

Medtronic CEO Omar Ishrak has long turned to emerging markets as a potential growth driver, and tapping into India's burgeoning population will play a key role in ramping up the company's business there, he said.

Report: Researchers develop neuron chips to direct movement of robotic prosthetics

Researchers have developed silicon chips that can be implanted in the brain and relay a person's intentions into the movement of robotic prosthetics.

MORE NEWS

From Our Sister Sites

FierceBiotech

A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a...

FiercePharma

The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.